Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Basilea Pharmaceutica AG    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/21/2019 06/24/2019 06/25/2019 06/26/2019 06/27/2019 Date
34.06(c) 34.12(c) 34.36(c) 35(c) 35.66 Last
79 614 28 543 54 475 63 745 18 788 Volume
-2.57% +0.18% +0.70% +1.86% +1.89% Change
More quotes
Financials (CHF)
Sales 2019 132 M
EBIT 2019 -24,2 M
Net income 2019 -32,1 M
Debt 2019 45,2 M
Yield 2019 -
Sales 2020 160 M
EBIT 2020 7,31 M
Net income 2020 2,05 M
Debt 2020 70,2 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 3,48x
EV / Sales2020 3,03x
Capitalization 416 M
More Financials
Company
Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of... 
More about the company
Surperformance© ratings of Basilea Pharmaceutica AG
Trading Rating : Investor Rating :
More Ratings
Latest news on BASILEA PHARMACEUTICA AG
06/03Basilea reports publication of clinical data for anticancer drug candidates B..
GL
05/02BASILEA PHARMACEUTICA : partner Avir Pharma has launched antifungal Cresemba® (i..
AQ
04/24BASILEA PHARMACEUTICA : Forge And Basilea Enter Into Multi-Target Agreement To D..
PR
04/10BASILEA PHARMACEUTICA : shareholders approve all proposals of the Board of Direc..
AQ
02/19BASILEA PHARMACEUTICA : reports strong revenue growth and significant pipeline p..
AQ
02/08Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milesto..
GL
02/07Basilea announces change in the Management Committee - Adesh Kaul appointed C..
GL
02/07BASILEA PHARMACEUTICA : announces change in the Management Committee - Adesh Kau..
GL
01/25Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecen..
AQ
01/24BASILEA PHARMACEUTICA : announces collaboration to study derazantinib and atezol..
GL
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Sector news : Biotechnology & Medical Research - NEC
06/26FDA Approves Sanofi, Regeneron Treatment for Chronic Rhinosinusitis with Nasa..
DJ
06/21Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
DJ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 86,5  CHF
Spread / Average Target 147%
EPS Revisions
Managers
NameTitle
David Veitch Chief Executive Officer
Domenico Scala Chairman
Donato Spota Chief Financial Officer
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BASILEA PHARMACEUTICA AG-12.41%385
IQVIA HOLDINGS INC33.97%30 697
LONZA GROUP27.13%24 626
CELLTRION, INC.--.--%23 271
INCYTE CORPORATION34.66%18 362
EXACT SCIENCES CORPORATION78.75%14 566